US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Spdr S&P Biotech Etf

154.51

-3.1700-2.01%

Pre-market: 155.801.29+0.83%05:05 EDT

Volume:11.57M

Turnover:1.81B

Market Cap:10.17B

PE:8.48

High:159.08

Open:156.99

Low:154.46

Close:157.68

52wk High:169.89

52wk Low:101.01

Shares:65.80M

Float Shares:65.80M

Volume Ratio:1.30

T/O Rate:17.59%

Dividend:0.55

Dividend Rate:0.35%

EPS(TTM):18.23

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Health Care Roundup: Market Talk

Yamashita Health Care Sees FY Net Y553.00m

Lonza Strengthens Board with Nomination of Biotech Veteran Pearl Huang

IHH Healthcare's Recent Weakness Likely Offers a Buying Opportunity

Veraxa Biotech Director Makes Bold Move With Fresh Insider Buy

Golden Globe Resources Sets Date and Digital Framework for 2026 AGM

Healthcare Stocks Declined as Consumer Confidence Slips

Health Care Roundup: Market Talk

Max Healthcare updates on adjourned NCLT case involving Kalinga Hospital subsidiary

Analyst Gil Blum Lifts Immix Biopharma Price Target to $30 on Strong NEXICART-2 Data and Accelerated Commercial Path

Analysts Are Bullish on Top Healthcare Stocks: Invivyd (IVVD), NewAmsterdam Pharma Company (NAMS)

Sara Nik Reiterates Buy on Moleculin as MIRACLE Trial De‑Risks AnnAraC; $3 Price Target Maintained

Health Care Roundup: Market Talk

Oncolytics announces publication of data on pelareorep in liver cancer

Wall Street Analysts Are Bullish on Top Healthcare Picks

Oncolytics Biotech® Announces Publication Demonstrating Pelareorep Creates Immune Responses in Liver Cancer That Make Tumors Susceptible to Immunotherapy

Sector Update: Healthcare Stocks Advance Pre-Bell Tuesday

MT Newswires Live

Moleculin Biotech completes enrollment in Part A of Phase 2/3 R/R MIRACLE trial

GPI Boosts Profitability and Foreign Growth on High-Margin Healthcare Software

Health Care Select Sector SPDR: Pivot points

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg1.tigeractivity.com/stock/XBI/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"XBI","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"XBI\",,,,,undefined,":{"symbol":"XBI","market":"US","secType":"STK","nameCN":"Spdr S&P Biotech Etf","latestPrice":154.51,"timestamp":1790884800000,"preClose":157.68,"halted":0,"volume":11574808,"hourTrading":{"tag":"盘前","latestPrice":155.8,"preClose":154.51,"latestTime":"05:05 EDT","volume":625,"amount":97178.12500000001,"timestamp":1790931905340,"change":1.29,"changeRate":0.008349,"amplitude":0.005301},"delay":0,"changeRate":-0.020104008117706847,"floatShares":65800000,"shares":65800000,"eps":18.23,"marketStatus":"Pre-Mkt","change":-3.17,"latestTime":"10-02 05:36:16 EDT","open":156.99,"high":159.0762,"low":154.46,"amount":1811920444.32,"amplitude":0.029276,"askPrice":155.9,"askSize":500,"bidPrice":155.1,"bidSize":500,"shortable":3,"etf":1,"ttmEps":18.23,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1790947800000},"marketStatusCode":1,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":154.51,"sharesOutstanding":63325000,"nav":157.70852,"aum":10290480910.03,"dividendRate":0.003547,"bidAskSpread":0.000327,"preHourTrading":{"tag":"盘前","latestPrice":155.8,"preClose":154.51,"latestTime":"05:05 EDT","volume":625,"amount":97178.12500000001,"timestamp":1790931905340,"change":1.29,"changeRate":0.008349,"amplitude":0.005301},"postHourTrading":{"tag":"盘后","latestPrice":155,"preClose":154.51,"latestTime":"19:57 EDT","volume":118007,"amount":18369076.5482,"timestamp":1790899064926,"change":0.49,"changeRate":0.003171,"amplitude":0.004466},"volumeRatio":1.3024388571095944,"optionData":{"bulkOrders":[{"symbol":"XBI","call":false,"expireDate":1791518400000,"strike":"148.0","timestamp":1790868578544,"price":0.46,"volume":2897,"amount":133262,"type":"-"},{"symbol":"XBI","call":false,"expireDate":1790913600000,"strike":"155.0","timestamp":1790868578544,"price":0.76,"volume":2897,"amount":220172,"type":"-"}]},"impliedVol":0.3251,"impliedVolPercentile":0.696},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"XBI\",,,,,undefined,":{"symbol":"XBI","floatShares":65800000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.3024388571095944,"shares":65800000,"dividePrice":0.5481,"high":159.0762,"amplitude":0.029276,"preClose":157.68,"low":154.46,"week52Low":101.01,"pbRate":"--","week52High":169.89,"institutionHeld":0.8511,"latestPrice":154.51,"eps":18.23,"divideRate":0.003547,"volume":11574808,"delay":0,"ttmEps":18.23,"open":156.99,"prevYearClose":121.93,"prevWeekClose":155.03,"prevMonthClose":157.68,"prevQuarterClose":157.68,"fiveDayClose":156.05,"twentyDayClose":165.37,"sixtyDayClose":162.97},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/XBI\",params:#limit:5,,,undefined,":[{"date":"2026-06-22","symbol":"XBI","amount":0.138094,"announcedDate":"2026-06-18","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-22","defaultRemindTime":1782135000000,"name":"SPDR S&P Biotech ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-24","payableDate":"2026-06-22","currency":"USD","dateTimestamp":1782100800000,"payDate":"2026-06-24"},{"date":"2025-12-22","symbol":"XBI","amount":0.406564,"announcedDate":"2025-12-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-22","defaultRemindTime":1766413800000,"name":"SPDR S&P Biotech ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-24","payableDate":"2025-12-22","currency":"USD","dateTimestamp":1766379600000,"payDate":"2025-12-24"},{"date":"2025-09-22","symbol":"XBI","amount":0.02665,"announcedDate":"2025-09-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-22","defaultRemindTime":1758547800000,"name":"SPDR S&P Biotech ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-24","payableDate":"2025-09-22","currency":"USD","dateTimestamp":1758513600000,"payDate":"2025-09-24"},{"date":"2025-06-23","symbol":"XBI","amount":0.007295,"announcedDate":"2025-06-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-23","defaultRemindTime":1750685400000,"name":"SPDR S&P Biotech ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-06-25","payableDate":"2025-06-23","currency":"USD","dateTimestamp":1750651200000,"payDate":"2025-06-25"},{"date":"2025-03-24","symbol":"XBI","amount":0.00525,"announcedDate":"2025-03-21","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-24","defaultRemindTime":1742823000000,"name":"SPDR S&P Biotech ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-03-26","payableDate":"2025-03-24","currency":"USD","dateTimestamp":1742788800000,"payDate":"2025-03-26"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"XBI\",market:\"US\",,,undefined,":[{"executeDate":"2016-12-16","recordDate":"2016-12-20","paymentDate":"2016-12-27","value":0.01831,"currency":"USD"},{"executeDate":"2017-03-17","recordDate":"2017-03-21","paymentDate":"2017-03-27","value":0.019702,"currency":"USD"},{"executeDate":"2017-06-16","recordDate":"2017-06-20","paymentDate":"2017-06-26","value":0.110135,"currency":"USD"},{"executeDate":"2017-09-15","recordDate":"2017-09-18","paymentDate":"2017-09-25","value":0.03704,"currency":"USD"},{"executeDate":"2018-03-16","recordDate":"2018-03-19","paymentDate":"2018-03-21","value":0.059081,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"XBI\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"XBI\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2671027487","title":"Health Care Roundup: Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2671027487","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671027487?lang=en_us&edition=fundamental","pubTime":"2026-09-30 16:20","pubTimestamp":1790756400,"startTime":"0","endTime":"0","summary":"The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET.0749 GMT - Fresenius investors might have overreacted to news th","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VOTE","LABU","BK4585","PMDE","BK4581","XBI","DECU","XLV","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671275727","title":"Yamashita Health Care Sees FY Net Y553.00m","url":"https://stock-news.laohu8.com/highlight/detail?id=2671275727","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671275727?lang=en_us&edition=fundamental","pubTime":"2026-09-30 15:00","pubTimestamp":1790751600,"startTime":"0","endTime":"0","summary":"Yamashita Health Care Holdings Inc. also released the following forecasts:. Results are based on Japanese accounting standards.This content was automatically published based on data and/or text from the original source. For feedback, write to singaporeeditors@dowjones.com.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4581","BK4585","LABU","BK4588","XBI","XLV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671278331","title":"Lonza Strengthens Board with Nomination of Biotech Veteran Pearl Huang","url":"https://stock-news.laohu8.com/highlight/detail?id=2671278331","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671278331?lang=en_us&edition=fundamental","pubTime":"2026-09-30 13:32","pubTimestamp":1790746351,"startTime":"0","endTime":"0","summary":"The latest update is out from Lonza Group Ltd ( ($CH:LONN) ). Lonza has nominated pharmaceutical and biotechnology veteran Pearl Huang as an indepe...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/lonza-strengthens-board-with-nomination-of-biotech-veteran-pearl-huang?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/lonza-strengthens-board-with-nomination-of-biotech-veteran-pearl-huang?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4581","IBB","LNGR","BK4585","BK4588","RSPH","XT","DARP","BBP","SYNB","FWD","XBI","IEIH","JDOC","FHLC","AGNG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671221962","title":"IHH Healthcare's Recent Weakness Likely Offers a Buying Opportunity","url":"https://stock-news.laohu8.com/highlight/detail?id=2671221962","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671221962?lang=en_us&edition=fundamental","pubTime":"2026-09-30 10:11","pubTimestamp":1790734260,"startTime":"0","endTime":"0","summary":"0211 GMT - IHH Healthcare's recent share price weakness is likely an enhanced buying opportunity, with Fortis-related litigation concerns expected to have limited impact on operations, says Citi analyst Megat Fais in a note. IHH says it isn't subject to financial claims in the dispute involving Daiichi Sankyo and former Fortis promoters. IHH's India plans remain on track to reach 10,000 beds target by 2030-2031, while Singapore's recovery is expected to continue, he reckons. Malaysia should see growth from selective bed additions and medical tourism, while Turkey's strong demand and international patient flows are expected to continue, he adds. Citi keeps a buy rating and its target price at 10.40 ringgit. Shares are 0.1% higher at 7.88 ringgit.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4137","LU0029874061.USD","DSNKY","LU0128526141.USD","BK4007","BK4581","BK4588","HCSG","LABU","XLV","BK4585","XBI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671412221","title":"Veraxa Biotech Director Makes Bold Move With Fresh Insider Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2671412221","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671412221?lang=en_us&edition=fundamental","pubTime":"2026-09-30 10:01","pubTimestamp":1790733716,"startTime":"0","endTime":"0","summary":"New insider activity at Veraxa Biotech ( ($VRXA) ) has taken place on September 29, 2026. Director Warren Hosseinion has recently strengthened his ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/veraxa-biotech-director-makes-bold-move-with-fresh-insider-buy-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/veraxa-biotech-director-makes-bold-move-with-fresh-insider-buy-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","BK4588","XBI","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671044225","title":"Golden Globe Resources Sets Date and Digital Framework for 2026 AGM","url":"https://stock-news.laohu8.com/highlight/detail?id=2671044225","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671044225?lang=en_us&edition=fundamental","pubTime":"2026-09-30 08:23","pubTimestamp":1790727806,"startTime":"0","endTime":"0","summary":"Reckon Health Care Holdings Ltd ( ($AU:GGR) ) has shared an announcement. Golden Globe Resources Limited has convened its 2026 Annual General Meeti...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/golden-globe-resources-sets-date-and-digital-framework-for-2026-agm?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/golden-globe-resources-sets-date-and-digital-framework-for-2026-agm?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","BK4581","BK4585","XBI","XLV","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671247293","title":"Healthcare Stocks Declined as Consumer Confidence Slips","url":"https://stock-news.laohu8.com/highlight/detail?id=2671247293","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671247293?lang=en_us&edition=fundamental","pubTime":"2026-09-30 04:58","pubTimestamp":1790715480,"startTime":"0","endTime":"0","summary":"On a losing day in Wall Street, the healthcare industry was no exemption. Stocks fell amid a surprising decline in the Conference Board Consumer Confidence Index.UniQure slid after patients treated with its Huntington's disease drug in a recent study no longer showed a statistically significant slowdown in disease-induced decline after four years. At four years, the study's primary endpoint--composite Unified Huntington's Disease Rating Scale --showed a 44% slowing of disease progression compared with an external control, but the data did not reach statistical significance, the company said.Novo Nordisk has signed a licensing deal for a weight-loss treatment being developed by Hengrui Pharma that could be worth up to $2.6 billion. The Danish drugmaker will pay China-based Hengrui $300 million upfront, with the rest of the potential deal value tied to milestones. Novo will obtain exclusive rights to develop, manufacture and commercialize HRS-1596 globally, excluding mainland China, Hong","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XLV","BK4581","XBI","BK4585","LU0029874061.USD","LU0128526141.USD","BK4588","BK4137","LABU","HCSG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671247428","title":"Health Care Roundup: Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2671247428","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671247428?lang=en_us&edition=fundamental","pubTime":"2026-09-30 04:50","pubTimestamp":1790715000,"startTime":"0","endTime":"0","summary":"The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET.1019 ET - Sterling shows little reaction after U.K. Prime Minist","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4581","BK4588","XLV","XBI","BK4585","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671241431","title":"Max Healthcare updates on adjourned NCLT case involving Kalinga Hospital subsidiary","url":"https://stock-news.laohu8.com/highlight/detail?id=2671241431","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671241431?lang=en_us&edition=fundamental","pubTime":"2026-09-30 02:03","pubTimestamp":1790705014,"startTime":"0","endTime":"0","summary":"The latest announcement is out from Max Healthcare Institute Ltd ( ($IN:MAXHEALTH) ). Max Healthcare Institute Ltd has updated exchanges on ongoing...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/max-healthcare-updates-on-adjourned-nclt-case-involving-kalinga-hospital-subsidiary?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/max-healthcare-updates-on-adjourned-nclt-case-involving-kalinga-hospital-subsidiary?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0029874061.USD","BK4137","LU0128526141.USD","BK4585","XLV","BK4588","LABU","BK4581","HCSG","XBI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671246794","title":"Analyst Gil Blum Lifts Immix Biopharma Price Target to $30 on Strong NEXICART-2 Data and Accelerated Commercial Path","url":"https://stock-news.laohu8.com/highlight/detail?id=2671246794","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671246794?lang=en_us&edition=fundamental","pubTime":"2026-09-30 00:55","pubTimestamp":1790700918,"startTime":"0","endTime":"0","summary":"Immix Biopharma, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Gil Blum from Needham reiterated a Buy rating...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/analyst-gil-blum-lifts-immix-biopharma-price-target-to-30-on-strong-nexicart-2-data-and-accelerated-commercial-path-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/analyst-gil-blum-lifts-immix-biopharma-price-target-to-30-on-strong-nexicart-2-data-and-accelerated-commercial-path-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","BK4585","LABU","BK4581","XBI","XLV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671743246","title":"Analysts Are Bullish on Top Healthcare Stocks: Invivyd (IVVD), NewAmsterdam Pharma Company (NAMS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2671743246","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671743246?lang=en_us&edition=fundamental","pubTime":"2026-09-30 00:40","pubTimestamp":1790700010,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Invivyd (IVVD), NewAmsterdam Pharma Company (NAMS) a...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-invivyd-ivvd-newamsterdam-pharma-company-nams-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-invivyd-ivvd-newamsterdam-pharma-company-nams-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LABU","LU0029874061.USD","XLV","BK4585","XBI","BK4588","LU0128526141.USD","BK4137","HCSG","BK4539","IVVD","NAMS","BK4139","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671124692","title":"Sara Nik Reiterates Buy on Moleculin as MIRACLE Trial De‑Risks AnnAraC; $3 Price Target Maintained","url":"https://stock-news.laohu8.com/highlight/detail?id=2671124692","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671124692?lang=en_us&edition=fundamental","pubTime":"2026-09-30 00:35","pubTimestamp":1790699727,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Sara Nik maintained a Buy rating on Moleculin Biotech today and set a price target of $3.00. Sara Nik has given his Buy rat...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/sara-nik-reiterates-buy-on-moleculin-as-miracle-trial-derisks-annarac-3-price-target-maintained-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/sara-nik-reiterates-buy-on-moleculin-as-miracle-trial-derisks-annarac-3-price-target-maintained-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","BK4588","XBI","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671246586","title":"Health Care Roundup: Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2671246586","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671246586?lang=en_us&edition=fundamental","pubTime":"2026-09-30 00:20","pubTimestamp":1790698800,"startTime":"0","endTime":"0","summary":"The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET.1019 ET - Sterling shows little reaction after U.K. Prime Minist","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4581","BK4585","XBI","XLV","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671210185","title":"Oncolytics announces publication of data on pelareorep in liver cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2671210185","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671210185?lang=en_us&edition=fundamental","pubTime":"2026-09-29 21:45","pubTimestamp":1790689517,"startTime":"0","endTime":"0","summary":"Oncolytics (ONCY) Biotech announced data published in the Proceedings of the National Academy of Sciences show pelareorep’s ability to change an im...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/oncolytics-announces-publication-of-data-on-pelareorep-in-liver-cancer-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/oncolytics-announces-publication-of-data-on-pelareorep-in-liver-cancer-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","BK4139","BK4581","BK4588","ONCY","XBI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671217785","title":"Wall Street Analysts Are Bullish on Top Healthcare Picks","url":"https://stock-news.laohu8.com/highlight/detail?id=2671217785","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671217785?lang=en_us&edition=fundamental","pubTime":"2026-09-29 21:30","pubTimestamp":1790688638,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Summit Therapeutics (SMMT) and Zymeworks (ZYME) with...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/wall-street-analysts-are-bullish-on-top-healthcare-picks-blurbs-news-361?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/wall-street-analysts-are-bullish-on-top-healthcare-picks-blurbs-news-361?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LABU","LU0029874061.USD","LU0128526141.USD","BK4139","BK4137","XBI","XLV","HCSG","SMMT","BK4588","BK4581","LU2488822045.USD","ZYME","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671210562","title":"Oncolytics Biotech® Announces Publication Demonstrating Pelareorep Creates Immune Responses in Liver Cancer That Make Tumors Susceptible to Immunotherapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2671210562","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671210562?lang=en_us&edition=fundamental","pubTime":"2026-09-29 21:30","pubTimestamp":1790688600,"startTime":"0","endTime":"0","summary":"Data support pelareorep’s potential as a backbone therapy to transform immunologically inactive liver tumors into a phenotype that will respond to immune-based interventionSAN DIEGO, Sept.  29, 2026 (","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/29/3370999/0/en/oncolytics-biotech-announces-publication-demonstrating-pelareorep-creates-immune-responses-in-liver-cancer-that-make-tumors-susceptible-to-immunotherapy.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XBI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671176842","title":"Sector Update: Healthcare Stocks Advance Pre-Bell Tuesday","url":"https://stock-news.laohu8.com/highlight/detail?id=2671176842","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671176842?lang=en_us&edition=fundamental","pubTime":"2026-09-29 21:24","pubTimestamp":1790688276,"startTime":"0","endTime":"0","summary":"Healthcare stocks were advancing pre-bell Tuesday, with the State Street Health Care Select Sector SPDR ETF  up 0.1% and the iShares Biotechnology ETF  0.3% higher.Iovance Biotherapeutics  stock was up more than 18% after the company raised its full year 2026 total revenue guidance to a range of $410 million to $420 million, from its prior outlook of $350 million to $370 million.UniQure  shares were down more than 47% after the company said additional data from its ongoing phase 1/2 studies of AMT-130 in Huntington's disease showed less pronounced benefits at 48 months.Pharming Group  has appointed chief commercial officer Leverne Marsh and chief financial officer Kenneth Lynard as interim co-chief executive officers, the company said. Pharming Group stock was down more than 3% pre-bell.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0109394709.USD","BK4585","LABU","LU0128526141.USD","LU0889565916.HKD","BK4139","BK4581","BK4588","PHAR","LU0029874061.USD","HCSG","QURE","XBI","XLV","IOVA","IBB","BK4137","LU0320765992.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671604212","title":"Moleculin Biotech completes enrollment in Part A of Phase 2/3 R/R MIRACLE trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2671604212","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671604212?lang=en_us&edition=fundamental","pubTime":"2026-09-29 20:56","pubTimestamp":1790686581,"startTime":"0","endTime":"0","summary":"Moleculin Biotech (MBRX) announced that it has completed and closed enrollment in Part A of its Phase 2/3 MIRACLE trial evaluating Annamycin in com...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/moleculin-biotech-completes-enrollment-in-part-a-of-phase-2-3-r-r-miracle-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/moleculin-biotech-completes-enrollment-in-part-a-of-phase-2-3-r-r-miracle-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","MBRX","BK4581","BK4139","XBI","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671121562","title":"GPI Boosts Profitability and Foreign Growth on High-Margin Healthcare Software","url":"https://stock-news.laohu8.com/highlight/detail?id=2671121562","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671121562?lang=en_us&edition=fundamental","pubTime":"2026-09-29 20:53","pubTimestamp":1790686381,"startTime":"0","endTime":"0","summary":"GPI SpA ( ($IT:GPI) ) has shared an announcement. GPI SpA reported first-half 2026 revenues of €256.4 million, broadly stable year on year, as grow...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/gpi-boosts-profitability-and-foreign-growth-on-high-margin-healthcare-software?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/gpi-boosts-profitability-and-foreign-growth-on-high-margin-healthcare-software?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HCSG","LU0128526141.USD","BK4214","VGT","BK4581","GPI","BK4137","LABU","BK4585","XBI","XLV","LU0029874061.USD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671231214","title":"Health Care Select Sector SPDR: Pivot points","url":"https://stock-news.laohu8.com/highlight/detail?id=2671231214","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671231214?lang=en_us&edition=fundamental","pubTime":"2026-09-29 20:38","pubTimestamp":1790685496,"startTime":"0","endTime":"0","summary":"The following are the pivot points for the Health Care Select Sector SPDR (XLV). Pivot High: $172.71, Pivot Low: $170.42. These were calculated usi...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/health-care-select-sector-spdr-pivot-points-thefly-news-152?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/health-care-select-sector-spdr-pivot-points-thefly-news-152?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","XLV","XBI","BK4585","LABU","BK4581"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":17,"pageCount":4,"totalSize":325,"code":"91000000","status":"200"}]}}